NSE / BSEHealthcare
₹2565.20+42.20+1.67%
P/E42.4Mkt Cap₹40.11 K CrEV/EBITDA—

GlaxoSmithkline Pharmaceuticals Ltd.

P/E42.4Mkt Cap₹40.11 K CrEV/EBITDA—
Company Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Valuation

Market Cap
₹0.00
Current Price
₹0
as of 16 Oct 2026
P/E Ratio
0.0x
P/B Ratio
0.0x
EV / EBITDA
—
EV / Sales
—
52W High
₹0
52W Low
₹0
Shares Out
0.00 Cr

Profitability

Operating Margin
—
Net Profit Margin
—
EBITDA Margin
—

Returns

ROE
—
ROCE
—
ROIC %
—
ROA
—
Dividend Payout
—

Solvency

Current Ratio
0.0x
Debt / Equity
0.0x
Debt / Assets
0.0x
CFO / Net Profit
—
Interest Coverage
—

AI Summary

Indian Stock

Strengths1

  • Large-cap with ₹40.1K Cr market capitalisation

Concerns0

    Rule-based from financial data. Not advice.

    Price History▼ 5.98% over 1Y

    Monthly Returns

    Unlock Monthly Returns

    Available on Pro and Institutional plans.

    Sign up free

    Year-to-Date ROI

    Unlock Year-to-Date ROI

    Available on Pro and Institutional plans.

    Sign up free

    Historical Volatility

    Unlock Historical Volatility

    Available on Pro and Institutional plans.

    Sign up free

    Historical Performance

    Revenue, profitability, and cash flow trends (₹ Crores)

    Revenue (10Y)

    Operating Income (10Y)

    Net Profit (10Y)

    Operating Margin % (10Y)

    Dividend Payout % (10Y)

    Free Cash Flow (10Y)

    Growth Summary

    Latest fiscal year: Mar 2025

    Revenue₹3.72 K Cr▲ 9.3%
    EBITDA Growth—
    Net Profit₹919.00 Cr▲ 57.1%
    Cash from Ops (CFO)—
    Free Cash Flow (FCF)—▲ 1381.3%
    Revenue CAGR 5Y—
    EBITDA CAGR 5Y—
    Net Profit CAGR 5Y—
    NP Growth 1Y57.1%

    Historical Growth

    Year-by-year revenue, profitability, and cash flow (₹ Crores, last 1 year)

    YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
    Mar 2025₹3.72 K Cr—₹919.00 Cr———9.3%57.1%

    Showing the latest year only. Sign up free for the full history.

    Financial Statements

    Income statement, balance sheet, and cash flow (₹ Crores, as reported)

    Showing the latest year only. Sign up free for the full history.

    Consolidated Figures in USD Millions.

    Unnamed: 0TTM
    Revenue / Net Sales3,767
    Total Expenses2,483
    EBIT / Operating Profit1,284
    OPM %34
    Other Income149
    Finance Costs3
    Depreciation & Amortisation68
    Profit Before Tax1,362
    Tax %-
    Net Profit / PAT997
    EPS (₹)58.85
    Dividend Payout %-

    Peer Comparison

    Healthcare sector peers, ranked by market cap

    CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
    GlaxoSmithkline Pharmaceuticals Ltd.this co.₹40.11 K Cr₹3.72 K Cr42.4023.46—9.3%
    Sun Pharmaceutical Industries Ltd.₹4.15 L Cr₹23.00 K Cr88.7017.4372.3013.5%
    Divi's Laboratories Ltd.₹1.71 L Cr₹9.20 K Cr67.9011.1367.2120.0%
    Torrent Pharmaceuticals Ltd.₹1.33 L Cr₹9.68 K Cr62.5015.7645.6413.5%
    Cipla Ltd.₹1.17 L Cr₹19.05 K Cr22.503.5119.3314.9%
    Apollo Hospitals Enterprises Ltd.₹1.05 L Cr₹8.20 K Cr75.0011.2854.4412.8%
    Max Healthcare Institute Limited₹1.00 L Cr₹2.66 K Cr144.0011.7696.8413.8%
    Industry Average—₹3.29 K Cr98.638.1165.5020.2%

    Learn while you research

    Hand-picked academy chapters to deepen your understanding of GlaxoSmithkline Pharmaceuticals Ltd. and the metrics that matter.

    Browse the full Equiscale Academy